Aclaris Therapeutics (ACRS) Change in Receivables (2018 - 2025)
Aclaris Therapeutics' (ACRS) quarterly Change in Receivables came in at -$56000.0 in Q2 2025, down 16.67% year-on-year from -$67200.0 in Q2 2024, and up 17.65% quarter-over-quarter from -$68000.0 in Q1 2025.
Aclaris Therapeutics (ACRS) Change in Receivables (2018 - 2025) Analysis & Trends
Aclaris Therapeutics' Change in Receivables history runs 8 years deep, the most recent figure standing at -$56000.0 for Q2 2025.
- On a quarterly basis, Change in Receivables fell 16.67% year-over-year to -$56000.0 in Q2 2025; TTM through Jun 2025 was -$131000.0, a 23.58% decrease from a year earlier, with the FY2024 full-year figure at $20000.0, up 110.75% from the prior year.
- Change in Receivables grew to -$56000.0 in Q2 2025 per ACRS's latest filing, from -$68000.0 in the prior quarter.
- Across five years, Change in Receivables topped out at $202000.0 in Q1 2023 and bottomed at -$255000.0 in Q2 2023.
- The 5-year median for Change in Receivables is -$44000.0 (2022), against an average of -$32111.1.
- Biggest YoY gain for Change in Receivables was 1920.0% in 2023; the steepest drop was 6475.0% in 2023.
- Year by year, Change in Receivables stood at -$188000.0 in 2021, then soared by 39.89% to -$113000.0 in 2022, then jumped by 57.52% to -$48000.0 in 2023, then jumped by 47.92% to -$25000.0 in 2024, then plunged by 124.0% to -$56000.0 in 2025.
- Per Business Quant, the three latest ACRS Change in Receivables figures stand at -$56000.0 (Q2 2025), -$68000.0 (Q1 2025), and -$25000.0 (Q4 2024).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 75.30 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 2.84 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -39.80 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -1.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Aclaris Therapeutics | 705.88 Mn | 705.88 Mn | 1.60 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -56,000.00 |
| Jun 30, 2025 | -56,000.00 |
| Mar 31, 2025 | -68,000.00 |
| Mar 31, 2025 | -68,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Dec 31, 2024 | -25,000.00 |
| Sep 30, 2024 | 18,000.00 |
| Sep 30, 2024 | 18,000.00 |
| Jun 30, 2024 | -48,000.00 |
| Jun 30, 2024 | -48,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Dec 31, 2023 | -48,000.00 |
| Dec 31, 2023 | -48,000.00 |
| Sep 30, 2023 | -85,000.00 |
| Sep 30, 2023 | -85,000.00 |
| Jun 30, 2023 | -255,000.00 |
| Jun 30, 2023 | -255,000.00 |
| Mar 31, 2023 | 202,000.00 |
| Mar 31, 2023 | 202,000.00 |